摘要
Abstract
To explore the safety profile and the clinical efficacy of paclitaxel, oxaliplatin, fluorouracil combined with autologous cytokine - induced killer ( CIK ) cell infusion in the treatment of advanced gastric cancer. Methods The clinical data of 34 patients in our department from May 2008 to March 2010 with historically or cytologically confirmed advanced gastric cancer were retrospectively analyzed. CIK cells were collected when the patients' white blood cell amounts were ≥ 8 × l09/L, and then cultured in laboratory. The drugs were administered as follows: paclitaxel 135 mg/m2, d2 , fluorouracil ( 5 - Fu ) 500 mg/d/m2 , intravenous continuous infusion chemotherapy pump d3～7, and oxaliplatin 100 mg/m2 , intravenously 3 h, d3 Matured CIK cell was reinfused, dl4. Each cycle lasted 21 days, and two cycles were evaluated for each patient. Results The overall effective rate was 70. 5% (24/34), which included complete response ( 2. 9% , 1/34), partial remission ( 67. 6% , 23/34 ), stable ( 23. 6% , 8/34 ), and progression ( 5. 9% , 2/34 ). The median time to progression was 8. 3 months, and the median survival was 11.2 months. The main toxicities included decreased peripheral blood cells, alopecia, and peripheral neurotoxicity. Conclusion Paclitaxel, oxaliplatin, fluorouracil combined with autologous CIK cell infusion have shown good efficacy and toxicity profiles in the treatment of advanced gastric cancer.关键词
胃肿瘤/紫衫醇/奥沙利铂/氟尿嘧啶/细胞因子诱导杀伤细胞/免疫疗法Key words
Stomach neoplasms/ Paclitaxel/ Oxaliplatin/ Fluorouracil/ Cytokine - induced killer cells/ Immuno- therapy分类
医药卫生
